Introduction to Europe Next Generation Sequencing (NGS) Market
The Europe NGS market was valued at $1.71 billion in 2023 and is expected to reach $5.72 billion by 2033, growing at a CAGR of 12.83% during the forecast period 2023-2033. The Next Generation Sequencing (NGS) market is experiencing growth primarily due to several key factors. These include the declining expenses associated with genome sequencing, the promising applications of NGS in oncology, the increasing prevalence of population-wide genomic research, governmental support for the integration of NGS in healthcare, and the superior attributes of NGS technology when compared to other sequencing methods.

Market Introduction
The Europe Next Generation Sequencing (NGS) market, specifically within the library preparation and sequencing segments, is witnessing substantial growth. Library preparation involves the crucial steps of DNA or RNA fragmentation, amplification, and indexing, making it a fundamental component of NGS workflows. In this context, the market is characterized by the increasing demand for high-throughput and efficient library preparation kits and systems, driven by the expanding applications of NGS in genomics research, clinical diagnostics, and personalized medicine.

The sequencing step, which follows library preparation, is equally significant. Europe’s NGS market is marked by a rising adoption of advanced sequencing platforms, including Illumina and Oxford Nanopore technologies, owing to their ability to deliver accurate and rapid sequencing results. This growth is fueled by the escalating need for genomic analysis in various fields, such as healthcare, agriculture, and microbiology, highlighting the pivotal role of library preparation and sequencing products in advancing NGS capabilities in the European region.

Market Segmentation:

Segmentation 1: by Offering

  • Consumables
    • Library Preparation Kits
    • Sequencing Kits
  • Equipment
  • Services



Segmentation 2: by Throughput

  • High- and Ultra-High-Throughput
  • Medium-Throughput
  • Low-Throughput



Segmentation 3: by Technology Type

  • Sequencing by Synthesis
  • In Torrent Semiconductor Sequencing
  • Single Molecule Real-Time Sequencing
  • Nanopore Sequencing Technology
  • Other Technologies



Segmentation 4: by Application

  • Clinical Diagnostics
    • Oncology
    • Non-Oncology
  • Research
    • Oncology
    • Non-Oncology


Segmentation 5: by Country

  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest-of-Europe



How can this report add value to an organization?
Type: The Europe NGS market has been segmented based on various categories, such as offerings, throughput, and platform, among others. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Competitive Strategy: The Europe NGS market is consolidated, with a few players accounting for most of the market share. Key players in the Europe NGS market analyzed and profiled in the study involve established players that offer various kinds of NGS platforms, consumables, and services.

Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Key Companies Profiled:

  • Oxford Nanopore Technologies plc
  • Qiagen N.V.
  • F. Hoffmann-La Roche Ltd
  • Centogene N.V.
  • Alithea Genomics


This report will be delivered in 1-5 working days.